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Abstract 
Backgroud and Aim: Chronic hepatitis C virus (HCV) infection is well 
known risk factor for hepatocellular carcinoma (HCC).  The aim of this 
study is to elucidate the genetic risk of development and recurrence of HCC 
in patients with HCV.  
Methods: A total of 468 patients with HCV, including 265 with HCC were 
enrolled.  We genotyped 89 SNPs in 81 genes expected to influence 
hepatocarcinogenesis using the iPLEX assay.  Risk of HCC was clarified 
by stratifying patients into risk groups based on the multiplied Odds Ratio 
(MOR) for SNPs associated with HCC, and the cumulative effects on the 
development and reccurence of HCC were analyzed.   
Results: Six SNPs associated with risk of HCC were identified (OR range: 
0.29~1.76).  These included novel SNPs for hepatocarcinogenesis with 
HCV CCND2 rs1049606, RAD23B rs1805329, CEP164 rs573455, and 
GRP78rs430397 in addition to the known SNPs MDM2 rs2279744 and 
ALDH2 rs671.  MOR analysis revealed that the highest risk group 
exerted about a 19 fold higher relative OR compared to the lowest risk 
group (p = 1.08 x 10 -5).  Predicted 10 year HCC risk ranged from 1.7% to 
96% depending on the risk group and the extent of fibrosis.  
Recurrence-free survival of RFA-treated HCC in the high risk group (n=53) 
was lower than that of low risk group (n=58, p = 0.038).   
Conclusion:  SNPs of CCND2, RAD23B, GRP78, CEP164, MDM2, and 
ALDH2 genes were significantly associated with development and 
recurrence of HCC in Japanese patients with HCV. 
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Introduction 
More than 170 million people worldwide are estimated to have 
chronic hepatitis C virus (HCV) infection.  The most important sequelae of 
chronic HCV infection are progressive liver fibrosis leading to cirrhosis and 
hepatocellular carcinoma (HCC), the latter responsible for significant 
morbidity and mortality throughout the world.[1-3]  Alcohol intake, older 
age at time of infection, male sex, and co-infection with hepatitis B virus 
accelerate disease progression in HCV- infected patients[4-6], but do not 
fully account for the development of HCC.   
As with many cancers, variants of genes involved in multistage 
carcinogenesis may determine an individual’s susceptibility to developing 
HCC.  Single nucleotide polymorphisms (SNPs) are the most common 
type of genomic sequence variation and are thought to be associated with 
population diversity, susceptibility to disease, and individual response to 
drug treatment.[7]  Many SNPs are silent, with no direct effect on gene 
products, but by virtue of linkage disequilibrium existing across the 
human genome they can be used as genetic markers to locate nearby 
functional variants that contribute to disease.  SNPs may also have 
functional consequences if they affect coding or regulatory (usually 
promoter) regions of genes.  Information accumulated from numerous 
studies on the association between cancer risk and SNPs in selected 
candidate genes may shed light on the molecular and genetic basis of the 
polygenic nature of cancer.   
We performed a search for SNPs in candidate genes associated with 
6 
 
susceptibility to the development of HCC.  A total of 88 SNPs in 81 genes 
were examined in Japanese patients with chronic HCV infection.  We 
identified two previously-reported and four novel variant SNPs as 
significant risk factors for incident HCC among patients with chronic HCV 
infection.  The six SNPs were also associated with recurrence of HCC. 
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Methods 
Study Subjects 
This case-control study included 468 Japanese patients with chronic 
HCV infection who were admitted to Okayama University Hospital or 
Kagawa Prefectural Central Hospital in Japan between January 2004 and 
December 2009. Patients comprised 265 with HCC and 203 without HCC.  
Chronic HCV infection was judged by a positive test for HCV antibody.  
We excluded patients who tested positive for the hepatitis B surface 
antigen.  Patients with HCC were newly diagnosed and the HCC were 
previously untreated.  Diagnosis of HCC was made by several imaging 
modalities, including angiography, computed tomography, and magnetic 
resonance imaging, or by tumor biopsy.  Diagnostic criteria for HCC via 
imaging were based on previous reports of hyper-attenuation at the 
arterial phase, hypo-attenuation at the portal phase in dynamic computed 
tomography (CT) or magnetic resonance imaging (MRI), and tumor 
staining on angiography.  According to guidelines of the American 
Association for the Study of Liver Disease, we confirmed HCC diagnosis 
using at least two dynamic imaging modalities.[8]  Nodules without 
positive imaging were histologically confirmed as HCC via 
ultrasound-guided, fine-needle biopsy.  Any patients imbibed over 80 
g/day alcohol for longer than 10 years were considered to have a positive 
history of alcohol abuse.  Age, gender, and information on clinical status 
were obtained for each patient at the time of whole-blood collection.  
Interferon had been administered to 61 (23%) cases and 49 (24%) controls, 
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with 12 (5%) and 11 (5%) sustained virologic responders.  Informed 
consent was obtained from all subjects.  The study protocol conformed to 
the ethical guidelines of the World Medical Association Declaration of 
Helsinki and was approved by The Bioethics Committee of Okayama 
University Medical School. 
 
Gene selection 
We selected 88 SNPs in 81 candidate genes considered to play a 
possible role in carcinogenesis by virtue of their ability to modify cell 
growth, hepatic inflammation, and/or hepatocyte apoptosis. (Table 1)  The 
candidate sites include genes related to growth factors, growth factor 
receptors, cytokines/chemokines, cytokine/chemokine receptors, apoptosis, 
tumor suppression, DNA repair, cell-cycle regulation, metabolism, cell-cell 
interaction, and chromosome segregation.  Most of them have been 
reported to be associated with carcinogenesis as well as HCC susceptibility. 
[9-31]  SNPs of the selected genes were extracted from the Japanese 
Single Nucleotide Polymorphisms database (http://snp.ims.u-tokyo.ac.jp), a 
database for SNPs found in the Japanese population, and from National 
Center for Biotechnology Information. 
 
Genotyping  
Genomic DNA was extracted from peripheral blood leukocytes using a 
QIAamp DNA blood mini kit (Qiagen, Hilden, Germany) according to the 
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instructions of the manufacturer. SNPs were genotyped using Sequenom® 
MassARRAY technology (Sequenom®, San Diego, CA, USA). The iPLEX™ 
assay was conducted according to the manufacturer’s instructions using 20 
ng of genomic DNA after classification into four groups of multiplex analyses. The 
primers for amplification and extension were designed using Mass ARRAY 
Assay Design v.3.1 software; primer sequences are available from the authors 
upon request. Briefly, DNA was amplified using PCR and the unincorporated 
nucleotide triphosphates were deactivated by phosphatase treatment 
shrimp alkaline phosphatase. A single base primer extension step was 
performed and allele-specific extension products of different masses were 
quantitatively analyzed using matrix-assisted laser desorption/ionization 
time of flight mass spectrometry (MALDI-TOF MS). 
 
Treatment and follow-up for HCC  
Among 265 HCC patients, 137 received radiofrequency ablation 
(RFA) as their first treatment modality, of whom 111 met the following 
inclusion criteria: HCC with size 3 cm and without extrahepatic 
metastasis, tumor number 3 or less, and Child-Pugh grade A or B.  After 
RFA, all patients underwent dynamic computed tomography (CT) or 
magnetic resonance imaging (MRI) and complete ablation was confirmed.  
The patients were followed regularly using abdominal ultrasound 
examination, CT, or MRI every 3 months.  All patients were followed until 
death or their last hospital visit. 
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Statistical Analysis 
Differences between cases and controls in the distributions of 
demographic characteristics were tested using Student’s t-test or the χ2 
test.  Tests for Hardy–Weinberg equilibrium were performed for each 
SNP separately among control subjects using Fisher’s exact test.  
Differences in allele frequencies between patients with and without HCC 
were tested for each SNP using the χ2 test.  Odds ratios (OR) and 95% 
confidence intervals (CI) were calculated using the major allele as 
reference.  Differences in genotype frequencies were tested using 
dominant, recessive, and overdominant genetic models for each SNP.  OR 
and 95% CI were estimated via unconditional logistic regression with a 
multiplicative model adjusting for age, gender, drinking history, and 
Child-Pugh grades (SPSS Ver.12.0, SPSS Inc, Tokyo, Japan).  
Permutation tests with 10,000 reiterations were performed using 
Haploview (http://www.broad.mit.edu/mpg/ haploview/) and declared 
statistically significant with p<0.05. 
We tested the combined effects of the six SNPs associated with HCC 
development by calculating a multiplied odds ratio (MOR) separately for 
each individual patient. The MOR is the product of ORs for all risk 
genotypes detected among the six SNPs in a patient, with adjusted ORs 
based on the best-fitting genetic models from single-SNP analyses.  When     
 calculating the MOR , we multiplied the risk ORs of six SNPs.  The MOR was 
11 
 
then categorized into five groups based on quintiles: very low, low, moderate, 
high, and very high risk.  The performance of each cutoff was determined 
in terms of discriminatory ability.  ORs, CIs, and p values for each MOR 
risk category were estimated using the very low risk group (lowest quintile 
of MOR) as the reference category.  
It has been reported that among untreated patients the annual 
incidence of HCC increases with degree of liver fibrosis, being 0.45% 
among patients with liver fibrosis stage 0 or 1, 1.99% with stage 2, 5.34% 
with stage 3, and 7.88% with stage 4 (cirrhosis).[32]  Based on the data 
and likelihood ratio (LR) of each MOR quintile risk category, we calculated 
the predicted 10-year absolute risk for HCC incidence (%) in each group 
according to stage of liver fibrosis as following. 
10-year risk =  ×100 
In this formula, Odds were converted from 10-year risk of HCC that was 
calculated from the reported annual incidence of HCC at each fibrosis 
stages. 
In the analysis of HCC recurrence after RFA, we combined the five 
MOR risk categories into two groups: one including very low, low, and 
moderate risk (n = 58), the other combining high and very high risk (n = 
53).  Cumulative recurrence rates were estimated using the 
Kaplan-Meier method and compared using the log rank test.  Because 
early development of HCC is thought to involve pre-existing intra-hepatic 
metastasis, we defined recurrence of HCC as a new legion that developed 
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more than three months after treatment, with the starting date of 
follow-up for tumor recurrence being the day when all tumors were ablated 
by RFA. 
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Results 
Patient characteristics are shown in Table 2.  There was no significant 
difference between HCC cases and controls in terms of alcohol intake, total 
bilirubin, prothrombin time, alanine aminotransferase (ALT) and IFN 
therapy.  Age, proportion of males, and proportion of Child-Pugh grade B 
were higher in patients with HCC than in patients without HCC, whereas 
serum albumin level and platelet count were lower in patients with HCC.  
 
SNPs related to HCC  
Among the 88 SNPs, we selected ones with minor allele frequency 
10%, genotyping success rate 95%, and no evidence of deviation from 
Hardy–Weinberg equilibrium (p<0.05) in control subjects.  Seventy-five 
SNPs satisfied these criteria, of which ten showed a positive association 
with HCC incidence (significant crude OR): CCND2 rs1049606, RAD23B 
rs1805329, miR-146a rs2910164, GRP78 rs430397, MDM2 rs2279744, 
ALDH2 rs671, TP53 rs1042522, WRN rs1801195, XPC rs2228000, and 
CEP164 rs573455.  To evaluate the effects of these polymorphisms on the 
occurrence of HCC, unconditional logistic regression analysis was 
performed with adjustment for age, gender, drinking history, and 
Child-Pugh grade.  As further validation, permutation tests for allele 
frequencies demonstrated significant differences with six SNPs: CCND2 
rs1049606, RAD23B rs1805329, MDM2 rs2279744, ALDH2 rs671, CEP164 
rs573455, and GRP78 rs430397 (Table 3).  After determining the best 
fitting genetic model for each variant (Table 4), CEP164 rs573455 had the 
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strongest association with HCC; adjusted OR for the CC genotype was 0.29 
(95% CI: 0.15-0.56, p=1.9 x 10 -4) using TT+TC as the reference. 
 
Prediction of HCC development by MOR  
MOR was calculated for the above-mentioned six SNPs to assess the 
cumulative effects on HCC incidence after inverting protective ORs (OR<1) 
(equivalently, using the OR for the reference genotype compared with risk 
genotype as reference). The risk genotype and risk OR for each SNP is 
shown in Table 4.  Calculated MOR ranged from 1.0 to 71.7 and was 
categorized into five groups using cutpoints 6, 13, 24, and 70.  The 
difference in the relative OR of HCC incidence among the risk categories 
was highly significant.  Compared with the very low risk group, relative 
OR of HCC was high in the very high risk group (OR=19.1, 95% CI: 
3.95-92.6, p=1.08×10 -5) (Table 5).  Table 5 also presents predicted 
cumulative incidence of HCC over 10 years according to stage of liver 
fibrosis in each MOR category.  Ten-year predicted cumulative incidence 
ranged widely from 1.67 in the very low risk group of F0 or 1 to 96.2% in 
the very high risk group of F4.  Within any particular fibrosis stage, the 
predicted incidence differed by anywhere from 1.7 to 15 fold among MOR 
categories, with the widest range in the lowest fibrosis stages. Even with 
fibrosis stage 0 or 1, predicted 10-year cumulative HCC incidence is 24.5% 
in the very high risk MOR group.  Interferon (IFN) therapy was conducted 
in 61 cases (23%) before development of HCC.  Twelve (5%) were 
sustained virologic responders and 49 (18%) were non-responders.  No 
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difference in MOR was observed between sustained virological responders 
and non-responders. 
 
Impact of MOR on Recurrence-Free Survival of RFA-treated HCC patients   
We compared the recurrence-free survival of RFA-treated patients 
between high risk and low risk groups.  Characteristics of the 111 
patients are shown in Table 6.  The high risk group was younger, but 
there was no significant difference in sex, tumor size, tumor number, 
alanine aminotransferase(ALT), total bilirubin, alubumin, platelet, 
prothrombin time, or alpha-fetoprotein. The median follow-up period was 
1043 days (range, 176-2533 days).  The 3-year cumulative recurrence 
rates were 77% in the high risk group and 59% in the low risk group.  
Patients in the high risk group had higher recurrence rates than those in 
the low risk group (p = 0.038) (Figure 1). 
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Discussion 
We studied 89 SNPs in 81 genes that were expected to be associated 
with hepatocarcinogenesis.  Putative genetic markers for susceptibility to 
hepatocarcinogenesis were identified in patients with chronic HCV 
infection. Six SNPs in six different genes were identified as being 
associated with HCC: CCND2 rs1049606, RAD23B rs1805329, MDM2 
rs2279744, ALDH2 rs671, GRP78 rs430397, and CEP164 rs573455. To our 
knowledge, the findings of associations linking CCND2 rs1049606, 
RAD23B rs1805329, and CEP164 rs573455 with HCC are novel.  The 
relationships of polymorphisms MDM2 rs2279744 and ALDH2 rs671 with 
HCC confirm previous results independently reported by other groups in 
Japan [30, 31, 33, 34].  
SNP rs1805329 (Ala249Val) is located in the RAD23B gene. The RAD23B 
protein is crucial in recognition and initiation of global genomic repair (GGR).  
SNP rs573455 (Gln1119Arg) is located in the CEP164 gene, which encode a 
centriole appendage protein and also associated with DNA repair. [35, 36]  SNP 
rs1049606 (T-171C) is located in 5’-UTR of the CCND2 gene.  The protein 
encoded by this gene is involved in phosphorylation of the 
tumor-suppressor protein Rb; abnormal levels of CCND2 are associated 
with poor prognosis in gastric cancer and intrahepatic recurrence in HCC. 
[37, 38]  SNP rs430397 (G/A) is located in intron 5 of the GRP78 gene and 
adjoins the 3’-end of the intron.  The GRP78 pathway, one of the most 
important responders to disease-associated stresses [39], demonstrates 
high correlation between expression and cancer progression, has 
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anti-apoptotic function, and leads to drug resistance in HCC.[40, 41]  
MDM2 (rs2279744) in the promoter region of the MDM2 gene, a negative 
regulator of p53, is associated with accelerated tumor formation in both 
hereditary and sporadic cancers in humans. [42]  SNP rs671 (Glu504Lys) is 
located in the ALDH2 gene.  ALDH2 is a key enzyme in the elimination of 
acetaldehyde. [43]  Our analysis revealed that heterozygotes for rs671 were 
associated with increased risk of HCC development; a similar result has been 
reported for esophageal cancer.[44]  All six genes are presumed to be 
associated with carcinogenesis.  However, functional effects of the four 
SNPs excluding ALDH2 and MDM2 have yet to be fully elucidated.  
We calculated joint effects on HCC development for the six 
polymorphisms by multiplying their separate odds ratios for each patient.  
Although gene-gene interaction is ignored using MOR, even if interaction 
exists the effects should influence cases and controls similarly.  
Furthermore, risk can be evaluated in greater detail by calculating the 
MOR of two or more genes compared with a single gene.  Previously, 
many studies demonstrated cumulative effects of SNPs in detecting the 
high risk group.[45, 46] Moreover, the high risk group may be refined by 
combining MOR with fibrosis stage, an indicator of carcinogenesis.  Yet 
even in the same fibrosis stage, the variation in predicted incidence of HCC 
can range anywhere from 1.7 to 15 fold.  If a patient has mild fibrosis 
(F0/F1/F2) but is in the high risk group based on MOR, predicted HCC 
incidence may be higher than for a patient in an advanced stage of fibrosis 
(F3/F4) with lower risk based on MOR.  According to the evidence-based 
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clinical practice guidelines for HCC in Japan,[47] screening is 
recommended once every 6 months for the high risk group (patients with 
chronic hepatitis B, C or with cirrhosis) and once every 3-4 months for the 
very high risk group (patients with cirrhosis type B or C).  By adding the 
concept of MOR, we can further refine the risk group and predict the 
incidence risk of HCC for each stage of fibrosis according to the risk 
categories stratified by MOR.  Our data suggest that MOR may 
occasionally be high even in patients whose fibrosis stage is 0 or 1.  Such 
patients are nevertheless at high risk of HCC, which indicates that SNP 
analysis complements other laboratory tests in identifying high-risk 
patients.   
Moreover, we found that the tumor recurrence rates following RFA 
therapy differed between patients in the high risk and low risk groups 
based on MOR category.  Those data increased the reliability of MOR in 
this study and suggest that we could predict not only risk of HCC 
development but also risk of recurrence.  By analyzing the SNPs, we could 
pay more attention during the surveillance of these high risk patients, and 
might achieve an early diagnosis of HCC. 
Several limitations of the present study should be noted.  
Histological examination, which is required for precise evaluation of liver 
fibrosis stage, was not performed on all of the non-cancerous tissues, 
although we used Child-Pugh grade as a parameter of liver function.  This 
study was lacking the data of HCV viral load or genotype which might be 
the risk factors of HCV related HCC.  In addition, the study design was 
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retrospective with a small number of patients.  A prospective study with 
larger sample is needed to confirm our results.  Moreover, validation 
study is needed to confirm the conclusion.  
Six SNPs : CCND2 rs1049606, RAD23B rs1805329, MDM2 
rs2279744, ALDH2 rs671, CEP164 rs573455, and GRP78 rs430397, are 
associated with risk of HCC among Japanese patients with chronic HCV 
infection. We could predict the absolute risk of HCC among HCV-related 
hepatitis patients by analyzing cumulative effects of these six SNPs using 
multiplied OR. The data were also effective for predicting patient’s 
prognosis. 
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FIGURE LEGEND 
 
Fig. 1 –  Recurrence free survival of high risk group and low risk group. 
Solid line, high risk group (n = 53); dotted line, low risk group (n = 58).   
High risk group patients had higher recurrence rate than those in low risk 
group (p = 0.038). 
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Table 1: SNPs analyzed 
Gene symbol NCBI SNP ID Gene symbol NCBI SNP ID 
ADH1B  rs1229984 IRF3  rs7251 
ADH1C  rs698 ITGAV rs2290083 
ALDH2 rs671† JUP  rs1126821 
ATR  rs2227928 LPL  rs328 
AURKA  rs2273535 MAD1L1  rs1801368 
AXIN2  rs2240308 MDM2 rs2279744† 
BARD1  rs2070094 miR-146a rs2910164† 
CASP9  rs1052571 miR-34b/c rs4938723 
CCND1 rs9344 MMP27 rs1276286 
CCND2 rs1049606† MMP9 rs17577 
CDC6 rs4134994 MTHFR  rs1801133 
CDH17 rs2514813  rs3214050 MTRR  rs10380 
CEP110  rs10818504 NIN rs2236316 
CEP152  rs2289181 NOB1  rs3811348 
CEP164  rs573455† NSL1  rs15702 
CEP192  rs578208 PCNT  rs2070425 
CEP250  rs3748433 PKCI rs481781 
CEP55  rs3740370  rs2293277 POL I  rs8305 
CEP57 rs644799 PTPN13  rs2230600  rs989902 
CEP68  rs12611491 PTPRJ rs1566734   rs1503185 
CEP72  rs868649 RAD18  rs373572 
CRHR2 rs2267716 RAD23B rs1805329† 
CTLA4 rs231775 RAG1  rs3740955 
CYP1B1 rs1056836 RAPGEF6  rs1291602 
CYP2C19  rs4986893 RASSF1  rs2073498 
DLC1 rs621554 RASSF6  rs12507775 
DUSP6  rs2279574 SCYB14 rs2237062 
EGF rs4444903 SNAI 1  rs4647958 
EGFR rs2293347   rs763317 SNM1B  rs11552449 
ERBIN rs36303 SPARC rs2304052 
ESR1 rs2077647 SRD5A2  rs523349 
ETL1  rs7439869 TDG rs4135113 
EXO1 rs4149963   rs1047840 TGFB1 rs1800469 
FSHR  rs6165 TP53  rs1042522† 
GFRA1 rs12762746 TRAP1 rs2074805 
GRP78 rs430397† WISP3  rs1230345 
GSTP1  rs1695 WRN  rs1801195† 
HER2 rs1136201 XPC rs2228000† 
IGF2 rs11541372 XPG rs17655 
IL10 rs1800872 XRCC  rs25487 
IL1B rs1143627   rs16944     
† SNPs with significantly different frequencies between cases and controls. 
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Table 2: Characteristics of the patients  
  Cases Controls p value * 
 Patients number 265 203   
Age (years) 68.4 (40-87) 57.7 (21-86) < 0.001 
Sex (male) 182 (68.7%) 100 (49.3%) < 0.001 
Alcohol >80 g/day  22 (8.3%) 13 (6.4%) 0.440 
TB (mg/dL) 1.1 (0.3-27.9) 1.3 (0.3-13) 0.423 
Albumin (g/dL) 3.6 (2.1-4.7) 3.9 (2.1-5.1) <0.001 
PT (%) 96 (54-146) 99 (23-152) 0.072 
ALT (IU/L) 54 (10-269) 61 (9-368) 0.087 
Platelet (×104/μL) 13 (2.1-41.9) 16 (1.5-34.7) 0.016 
Child-Pugh grade    
A 217 (81.9%) 173 (85.2%) 0.003 
B 43 (16.2%) 17 (8.4%)  
C 5 (1.9%) 13 (6.4%)  
IFN therapy 61(23%) 49(24%) 0.777 
Values are median (range) or number (%).   
Abbreviations: TB, total bilirubin; PT, prothrombin time; ALT, alanine 
aminotransferase; IFN, interferon. 
* p values were derived from the Pearson χ2 test or student's t test. 
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Table 3: Alleles and genotype frequencies of six SNPs demonstrating a 
significant difference between cases and controls 
Gene symbol 
Chromosomal 
Region 
SNP ID Alleles 
MAF 
OR 95% CI  
Permutation 
p value† 
Genotype Case Control p value* 
Case Control 
  (%) (%)     (n) (n)  
CCND2 rs1049606 T / C 37.5 46.6 0.69 0.53-0.90 0.0051 TT 99 64  
2p13.321        TC 133 89 0.869 
        CC 33 50 0.001 
RAD23B rs1805329 C / T 17.2 25.6 0.60 0.44-0.83 0.003 CC 180 117  
9q31.2        CT 79 68 0.167 
        TT 6 18 6.8×10-4 
GRP78 rs430397 G / A 15.1 10.0 1.58 1.06-2.36 0.034 GG 192 164  
9q33.3        GA 66 37 0.068 
        AA 7 2 0.155 
MDM2 rs2279744 G / T 40.9 47.7 0.76 0.58-0.99 0.038 GG 88 56  
12q15        GT 129 96 0.471 
        TT 41 47 0.031 
ALDH2 rs671 G / A 29 21.6 1.48 1.09-2.01 0.012 GG 132 126  
12q24.12        GA 111 60 0.004 
        AA 21 13 0.244 
CEP164 rs573455 T / C 38.7 45.4 0.76 0.58-0.99 0.035 TT 88 61  
11q23.3        TC 138 93 0.895 
        CC 30 43 0.012 
Abbreviation: MAF, minor allele frequency 
*  χ2 test for 2×2 contingency table 
† Permutation tests with 10,000 reiterations were performed by the 
Haploview program 
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Table 4: Best-fitting model fit to data on six SNPs with significant 
case-control frequency differences  
  Best-Fitting Model†     
Gene symbol SNP ID Model Genotype Adj OR (95%CI) p value* Risk genotype Risk OR 
   Reference Associated     
CCND2 rs1049606 Recessive TC+TT CC 0.50 (0.28-0.88) 0.016 TC+TT 2.00 
RAD23B rs1805329 Dominant CC CT+TT 0.56 (0.36-0.89) 0.013 CC 1.79 
GRP78 rs430397 Dominant GG GA+AA 1.76 (1.04-2.96) 0.035 GA+AA 1.76 
MDM2 rs2279744 Recessive GT+GG TT 0.50 (0.28-0.87) 0.014 GT+GG 2.00 
ALDH2 rs671 Overdominant GG+AA GA 1.64 (1.03-2.60) 0.037 GA 1.64 
CEP164 rs573455 Recessive TC+TT CC 0.29 (0.15-0.55) 1.9×10-4 TC+TT 3.45 
Abbreviation: Adj OR, adjusted odds ratio 
† The  best-fitting model for each SNP was determined after testing 
association in a series of genetic models, including dominant, recessive and 
overdominant models. 
*  Ors of genotypes and minor alleles were calculated by logistic regression 
adjusted for age, sex, alcohol drinking, and Child-Pugh grade and 95%CIs 
and p values were derived from the Wald test.  
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Table 5: Predicted HCC incidence calculated according to the joint effects of 
six SNPs 
Category 
MOR 
Range 
Case Control OR (95% CI) p value* LR 
10-year predicted HCC incidence 
(%) 
n = 265 n = 203    F0 or 1 F2 F3 F4 
  n (%) n (%)    mean = 4.5 19.9 53.4 78.8 
Very low risk 1 - 6 16  (6.0) 34 (16.7) 1.00 (Ref.) 1 0.36 1.67 8.20 29.2 57.2 
Low risk 6 - 13 60 (22.6) 62 (30.5) 2.06 (1.03-4.11) 0.043 0.74 3.37 15.5 45.9 73.3 
Moderate risk 13 - 24 62 (23.4) 48 (23.6) 2.74 (1.36-5.55) 0.006 0.99 4.45 19.7 53.2 78.6 
High risk 24 - 70 109 (41.1) 57 (28.1) 4.06 (2.07-7.98) 3.46×10 -5 1.46 6.44 26.6 62.6 84.4 
Very high risk 70 < 18  (6.8) 2 (1.0) 19.1 (3.95-92.6) 1.08×10 -5 6.89 24.5 63.1 88.8 96.2 
Abbreviations: MOR, multiplied odds ratio; Ref、reference; LR, likelihood 
ratio; F, stage of liver fibrosis 
* p values were calculated using Fisher's exact test (two-sided) 
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Table 6: Characteristics of RFA-treated patients 
 High risk group Low risk group  
 (n = 53) (n = 58) p value* 
Age (years) 67.3 (40-83) 70.9 (52-85) 0.027 
Sex （male） 28 (53%) 33 (57%) 0.670 
Tumor size (mm) 16 (9-29) 16 (6-30) 0.606 
Tumor number (single) 34 (64%) 46 (79%) 0.156 
ALT (IU/L) 55 (17-235) 57 (21-164) 0.696 
TB (mg/dL) 0.9 (0.4-2.2) 0.9 (0.4-1.9) 0.540 
Albumin (g/dL) 3.6 (2.7-4.6) 3.7 (2.8-4.6) 0.215 
Platelet count (×104/μL) 11.2 (3.1-21.5) 11.1 (4.4-30.7) 0.911 
PT (%) 97.8 (71-146) 97.8 (56-140) 0.990 
AFP (μg/L) 71.3 (1.9-925) 97.9 (3.2-2818) 0.635 
Values are median (range) or number (%). 
Abbreviations: ALT, alanine aminotransferase; TB, total bilirubin; PT, 
prothrombin time; AFP, α-fetoprotein 
* p values were derived from either the Pearson χ2 test or student's t test. 
 
 
 
 
 
 
